Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:42:02.065Z.
Consensus retrieved: 2026-10-06T12:00:58.963Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:42:02.065Z.
Quote observation: 2026-10-06T15:36:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b6268879a98e6c39cef7c3f9e2e80a63ea5355fd191f52e510f01db01fc6dd59
Forward PE Ratio (N/A) = Dated Quote Price ($16.82) / Consensus Forward EPS ($-1.38)
FORWARD PE RATIO
N/A
Greenwich LifeSciences, Inc.
Market Cap
$246.89M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $246.89M | N/A |
| Q32 Bio Inc. (QTTB)vs › | $247.49M | N/A |
| Invivyd, Inc. (IVVD)vs › | $247.82M | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $249.41M | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.62M | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $242.78M | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $242.35M | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $241.89M | N/A |
| InflaRx N.V. (IFRX)vs › | $241.56M | N/A |
| Quantum-Si incorporated (QSI)vs › | $252.22M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $16.82, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.39 | $-1.47 – $-1.29 | 2 | n/m |
| 2027-12-31 | $-1.17 | $-1.17 – $-1.17 | 1 | n/m |
| 2028-12-31 | $3.98 | $3.98 – $3.98 | 1 | 4.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
